 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- ISIKOK-19 / Acıbadem Healthcare, Acıbadem University
ISIKOK-19 CAR T Cell in ALL with Extramedullary Disease (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_102;
P1/2
In conclusion, the administration of ISIKOK-19 CAR-T therapy in this small patient group with EMD achieved safety and efficacy outcomes. These preliminary results make us believe that ISIKOK-19 CAR-T constitutes a potential therapeutic option in such a high unmet medical need.
- | ISIKOK-19 / Acıbadem Healthcare, Acıbadem University
Journal: Preliminary Report of Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application. (Pubmed Central) - Aug 27, 2022
P1/2
These preliminary results make us believe that ISIKOK-19 CAR-T constitutes a potential therapeutic option in such a high unmet medical need. No abstract available
- Darzalex IV (daratumumab) / J&J
SUCCESSFULL MANAGEMENT OF POST- CAR-T CELL COLD AGLUTININ MEDIATED REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA WITH DARATUMUMAB (ePoster Area [VIRTUAL]) - Jan 30, 2022 - Abstract #EBMT2022EBMT_1219;
Cold agglutinin mediated hemolytic anemia post CAR-T cell treatment is a complex entity with lack of evidence based treatment . Anti CD38 monoclonal antibody daratumumab induces rapidly depletion of antibody producing plasma cells and can be an option in steroid, IVIG and Rituximab refractory cold agglutinin mediated autoimmune hemolytic anemia in CAR-T cell patients.
- | ISIKOK-19 / Acıbadem Healthcare, Acıbadem University
Preclinical, Journal, CAR T-Cell Therapy: Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) targeting CD19-expressing B Cells for the First Turkish Academic Clinical Trial with Relapsed/refractory ALL and NHL Patients. (Pubmed Central) - Jul 30, 2021
In addition, ISIKOK-19 cells demonstrated a significant high level of cytotoxicity specifically against a CD19+ B-lymphocyte cancer model, RAJI cells, in NOD/SCID mice. This is the first report of preclinical assessment of efficacy and safety analysis of CAR-T cells (ISIKOK-19) targeting CD19-expressing B cells in relapsed/refractory ALL and NHL patients in Turkey.
- | ISIKOK-19 / Ac?badem Healthcare, Ac?badem University
Trial primary completion date, CAR T-Cell Therapy: ISIKOK-19: Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL (clinicaltrials.gov) - Jan 27, 2020
P1/2, N=24, Recruiting, Sponsor: Acibadem University
This is the first report of preclinical assessment of efficacy and safety analysis of CAR-T cells (ISIKOK-19) targeting CD19-expressing B cells in relapsed/refractory ALL and NHL patients in Turkey. Trial primary completion date: Jan 2020 --> Jan 2021
- | ISIKOK-19 / Ac?badem Healthcare, Ac?badem University
New P1/2 trial, CAR T-Cell Therapy: ISIKOK-19: Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL (clinicaltrials.gov) - Dec 19, 2019
P1/2, N=24, Recruiting, Sponsor: Acibadem University